uniQure NVQURE +1.00%52 Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates QURE with a GF Score™ of 52/100 and a GF Value™ of $5.95 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 151 Biotechnology companies, uniQure NV ranks worse than 662250.99% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of uniQure NV is 0.00%.
The historical rank and industry rank for uniQure NV's Dividend Yield % or its related term are showing as below:
QURE's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for uniQure NV's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QURE vs NVAX, HRMY, IOVA: Dividend Yield % Comparison
For the Biotechnology subindustry, uniQure NV's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where uniQure NV's Dividend Yield % falls into.
uniQure NV (QURE) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #999999 out of 151 companies in the Biotechnology industry.
Is uniQure NV's Dividend Yield % too high?
uniQure NV's current Dividend Yield % is 0.00%. Based on the distribution chart, uniQure NV ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, uniQure NV has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Dividend Yield % compare to NVAX and HRMY?
According to the Biotechnology industry distribution chart, uniQure NV ranks #999999 out of 151 companies for Dividend Yield %. This places uniQure NV in the lower half of its industry. The industry median Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.50, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on uniQure NV and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (QURE) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.95, compared to a current price of $49.34 — trading 729.2% above its estimated fair value. The current Dividend Yield % is 0.00%. uniQure NV's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For uniQure NV (QURE), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (QURE) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of $49.34 is trading 729.2% above its estimated GF Value™ of $5.95.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for QURE:
Dividend Yield %: 0.00%
GF Value™: $5.95 vs. price of $49.34 (729.2% above fair value)
No single metric tells the full story. See the QURE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
52GF Score
Get the complete analysis for QURE
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QURE has been successfully added to your 
